NO20015298L - Metabolsk intervensjon med GLP-1 eller dets biologisk aktive analoger for å forbedre funksjonen til den iskemiske ogreperfunderte hjerne - Google Patents

Metabolsk intervensjon med GLP-1 eller dets biologisk aktive analoger for å forbedre funksjonen til den iskemiske ogreperfunderte hjerne

Info

Publication number
NO20015298L
NO20015298L NO20015298A NO20015298A NO20015298L NO 20015298 L NO20015298 L NO 20015298L NO 20015298 A NO20015298 A NO 20015298A NO 20015298 A NO20015298 A NO 20015298A NO 20015298 L NO20015298 L NO 20015298L
Authority
NO
Norway
Prior art keywords
glp
ischemic
improve
function
biologically active
Prior art date
Application number
NO20015298A
Other languages
English (en)
Norwegian (no)
Other versions
NO20015298D0 (no
Inventor
Thomas R Coolidge
Mario R W Ehlers
Original Assignee
Bionebraska Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bionebraska Inc filed Critical Bionebraska Inc
Publication of NO20015298D0 publication Critical patent/NO20015298D0/no
Publication of NO20015298L publication Critical patent/NO20015298L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
NO20015298A 1999-04-30 2001-10-29 Metabolsk intervensjon med GLP-1 eller dets biologisk aktive analoger for å forbedre funksjonen til den iskemiske ogreperfunderte hjerne NO20015298L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/303,016 US6429197B1 (en) 1998-10-08 1999-04-30 Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain
PCT/US2000/011652 WO2000066142A2 (fr) 1999-04-30 2000-05-01 Intervention metabolique a l'aide de glp-1 ou de ses analogues biologiquement actifs pour ameliorer la fonction cerebrale apres ischemie et reperfusion

Publications (2)

Publication Number Publication Date
NO20015298D0 NO20015298D0 (no) 2001-10-29
NO20015298L true NO20015298L (no) 2001-12-28

Family

ID=23170209

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20015298A NO20015298L (no) 1999-04-30 2001-10-29 Metabolsk intervensjon med GLP-1 eller dets biologisk aktive analoger for å forbedre funksjonen til den iskemiske ogreperfunderte hjerne

Country Status (14)

Country Link
US (2) US6429197B1 (fr)
EP (1) EP1187628B1 (fr)
JP (1) JP2002543145A (fr)
CN (1) CN1376072A (fr)
AT (1) ATE369873T1 (fr)
AU (2) AU774084B2 (fr)
CA (1) CA2368772C (fr)
DE (1) DE60035987T2 (fr)
ES (1) ES2290029T3 (fr)
IL (1) IL145829A0 (fr)
MX (1) MXPA01010937A (fr)
NO (1) NO20015298L (fr)
NZ (1) NZ514609A (fr)
WO (1) WO2000066142A2 (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849708B1 (en) * 1986-05-05 2005-02-01 The General Hospital Corporation Insulinotropic hormone and uses thereof
US7138486B2 (en) * 1986-05-05 2006-11-21 The General Hospital Corporation Insulinotropic hormone derivatives and uses thereof
US6924264B1 (en) * 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US20060160740A1 (en) * 1999-10-21 2006-07-20 Suad Efendic Use of GLP-1 or analogs in treatment of stroke
EP1282436B1 (fr) 2000-05-19 2008-06-11 Amylin Pharmaceuticals, Inc. Traitement du syndrome coronarien aigu par glp-1
DK1294757T3 (da) * 2000-06-16 2007-03-19 Lilly Co Eli Glucagonlignende peptid 1-analoger
US7090869B2 (en) 2000-12-01 2006-08-15 Takeda Pharmaceutical Company Limited Method for producing preparation containing bioactive substance
JP2002293799A (ja) * 2001-03-29 2002-10-09 Itoham Foods Inc 新規ペプチド及びそれを含有する消化管運動抑制剤
DE60228972D1 (de) * 2001-07-31 2008-10-30 Us Gov Health & Human Serv Glp 1 exendin 4 peptidanaloga und deren verwendungen
EP2277910A1 (fr) 2001-12-21 2011-01-26 Human Genome Sciences, Inc. Protéines de fusion d'albumine
WO2004071393A2 (fr) * 2003-02-13 2004-08-26 Bayer Healthcare Ag Diagnostic et therapeutique pour des maladies associees au recepteur peptide 1 de type glucagon
ES2737835T3 (es) 2003-04-23 2020-01-16 Valeritas Inc Bomba accionada hidráulicamente para la administración de medicamentos de larga duración
US20080194483A1 (en) * 2003-12-12 2008-08-14 Brownlee Michael A GLP-1 (9-36) methods and compositions
CA2550217A1 (fr) * 2003-12-12 2005-07-07 Michael A. Brownlee Glp-1 (9-36): methodes et compositions
US9089636B2 (en) 2004-07-02 2015-07-28 Valeritas, Inc. Methods and devices for delivering GLP-1 and uses thereof
ES2566058T3 (es) 2006-03-30 2016-04-08 Valeritas, Inc. Dispositivo de suministro de fluidos de múltiples cartuchos
US8986253B2 (en) 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
WO2010013012A2 (fr) * 2008-08-01 2010-02-04 Lund University Bioscience Ab Polypeptides inédits et leurs utilisations
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
CA2737461A1 (fr) 2008-09-19 2010-03-25 Tandem Diabetes Care, Inc. Dispositif de mesure de la concentration d'un solute et procedes associes
US8926561B2 (en) 2009-07-30 2015-01-06 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
CN101706297B (zh) * 2009-08-10 2012-10-17 浙江鼎立实业有限公司 数显式微压和微流量综合检测台
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
US9555186B2 (en) 2012-06-05 2017-01-31 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
JP6224586B2 (ja) 2012-07-10 2017-11-01 武田薬品工業株式会社 注射用製剤
CN103566354B (zh) * 2012-07-25 2017-12-05 江苏豪森药业集团有限公司 含有glp‑1类似物的衍生物或其可药用盐的药物组合物
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
WO2014096150A1 (fr) 2012-12-21 2014-06-26 Sanofi Agonistes du glp1/gip double ou du glp1/gip/glucagon trigonal
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
EP3080152A1 (fr) 2013-12-13 2016-10-19 Sanofi Analogues peptidiques de l'exendine 4 non acylés
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／升糖素受體促效劑
TW201609795A (zh) 2013-12-13 2016-03-16 賽諾菲公司 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
EP3080154B1 (fr) 2013-12-13 2018-02-07 Sanofi Agonistes doubles du récepteur glp-1/gip
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
AU2017261216B2 (en) * 2016-05-06 2023-08-03 Immunoforge Co., Ltd. ELP fusion proteins for controlled and sustained release

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196196A (en) * 1978-06-19 1980-04-01 Tiholiz Ivan C Divalen/monovalent bipolar cation therapy for enhancement of tissue perfusion and reperfusion in disease states
US4976959A (en) * 1986-05-12 1990-12-11 Burroughs Wellcome Co. T-PA and SOD in limiting tissue damage
US6204259B1 (en) * 1993-01-14 2001-03-20 Monsanto Company Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
US5424286A (en) * 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5373016A (en) 1993-05-28 1994-12-13 Zeneca, Inc. Protection of isothiazolinone biocides from free radicals
US5574008A (en) 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US6277819B1 (en) 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
CA2277112C (fr) 1997-01-07 2008-08-26 Amylin Pharmaceuticals, Inc. Utilisation d'exendines et de leurs agonistes pour reduire la consommation alimentaire
US5846937A (en) 1997-03-03 1998-12-08 1149336 Ontario Inc. Method of using exendin and GLP-1 to affect the central nervous system
WO1998043658A1 (fr) * 1997-03-31 1998-10-08 Eli Lilly And Company Analogues de peptide 1 assimile au glucagon (glp-1)
MY155270A (en) * 1998-09-24 2015-09-30 Lilly Co Eli Use of glp-1 or analogs in treatment of stroke
US6284725B1 (en) 1998-10-08 2001-09-04 Bionebraska, Inc. Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
JP4480329B2 (ja) 2000-10-20 2010-06-16 アミリン・ファーマシューティカルズ，インコーポレイテッド Ｇｌｐ−１ペプチドによる冬眠心筋および糖尿病性心筋症の治療

Also Published As

Publication number Publication date
CA2368772C (fr) 2011-11-15
IL145829A0 (en) 2002-07-25
JP2002543145A (ja) 2002-12-17
USRE41288E1 (en) 2010-04-27
NZ514609A (en) 2004-03-26
WO2000066142A3 (fr) 2002-01-24
DE60035987T2 (de) 2008-05-08
ES2290029T3 (es) 2008-02-16
CA2368772A1 (fr) 2000-11-09
AU2004212547B2 (en) 2008-03-20
AU2004212547A1 (en) 2004-10-14
NO20015298D0 (no) 2001-10-29
MXPA01010937A (es) 2002-05-06
AU4682500A (en) 2000-11-17
WO2000066142A2 (fr) 2000-11-09
EP1187628B1 (fr) 2007-08-15
AU774084B2 (en) 2004-06-17
CN1376072A (zh) 2002-10-23
EP1187628A2 (fr) 2002-03-20
ATE369873T1 (de) 2007-09-15
DE60035987D1 (de) 2007-09-27
US6429197B1 (en) 2002-08-06

Similar Documents

Publication Publication Date Title
NO20015298D0 (no) Metabolsk intervensjon med GLP-1 eller dets biologisk aktive analoger for å forbedre funksjonen til den iskemiske ogreperfunderte hjerne
MXPA05006994A (es) Composiciones y metodos para la prevencion y el control de hipoglucemia inducida por insulina.
CA2373266A1 (fr) Utilisation d'exendines et de leurs agonistes pour le traitement du diabete sucre gestationnel
CA2395165A1 (fr) Traitement du myocarde hibernant et de la cardiomiopathie diabetique par un peptide glp-1
CO5700796A2 (es) Composiciones que contienen piperacilina y tazobactam utiles para inyecciones
AR032567A1 (es) Propeptidos gdf modificados y estabilizados y usos de los mismos
NO20015294L (no) Metabolsk intervensjon med GLP-1 for å forbedre funksjonen av iskemisk og reperfundert vev
EP1425031B8 (fr) Lipoproteines de haute densite (hdl) pour le traitement des accidents vasculaires cerebraux (avc) et autres evenements ischemiques
BR9913932A (pt) Uso de análogos de glp-1 no tratamento de derrame
DK1317419T3 (da) Cyanophenoxycarboxylsyre-forbindelser og sammensætninger til at levere aktive midler
MX2007009312A (es) Preparaciones inyectables de diclofenaco y sus sales farmaceuticamente aceptables.
HK1052139A1 (en) Method and composition for the treatment of adenoviral ocular infections
EA200000141A1 (ru) Способ лечения диабета тиазолидиндионом и сульфонилмочевиной
RU2003113987A (ru) Способ лечения и профилактики заболеваний воздействием на биологически активные точки и зоны
EA199901103A1 (ru) Антивирусный препарат для инъекций
ECSP982542A (es) Nuevo metodo de tratamiento iii
ECSP982534A (es) Nuevo metodo de tratamiento
CO5150158A1 (es) Tratamiento antidiabetico novedoso
RU2003138011A (ru) Способ лечения хронического пиелонефрита
DE60306344D1 (de) Behandlung von typ i diabetes mellitus mit wachstumshormonantagonisten
ECSP982591A (es) Nuevo metodo de tratamiento iv
UA116600U (uk) Спосіб лікування гострого ішемічного інсульту
RU99116894A (ru) Способ профилактики пролиферативной витреоретинопатии
ECSP982593A (es) Nuevo metodo de tratamiento vi
UA37442A (uk) Спосіб впливу на фолікулогенез яєчників самиць

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application